Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

Oncotarget. 2021 Aug 17;12(17):1736. doi: 10.18632/oncotarget.28051.

Teru Hideshima¹, Ralph Mazitschek², Jun Qi¹, Naoya Mimura^{1

3}, Jen-Chieh Tseng^{4

5}, Andrew L Kung^{4

6

7}, James E Bradner^{1

8}, Kenneth C Anderson¹

¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
² Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Department of Hematology, Chiba University Hospital, Chiba, Japan.
⁴ Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, USA.
⁵ PerkinElmer Inc., Hopkinton, MA, USA.
⁶ Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Boston, MA, USA.
⁷ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.19019.].